# A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation

> **NCT05789082** · PHASE1,PHASE2 · RECRUITING · sponsor: **Hoffmann-La Roche** · enrollment: 320 (estimated)

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Divarasib
- **DRUG:** Pembrolizumab
- **DRUG:** Carboplatin
- **DRUG:** Cisplatin
- **DRUG:** Pemetrexed

## Key facts

- **NCT ID:** NCT05789082
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-06-20
- **Primary completion:** 2032-01-29
- **Final completion:** 2032-01-29
- **Target enrollment:** 320 (ESTIMATED)
- **Last updated:** 2026-04-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05789082

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05789082, "A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05789082. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*